Skip to main content

Case 1: Mild Cognitive Impairment (MCI)—[18F]FDG and Amyloid PET

  • Chapter
  • First Online:
Clinical Nuclear Medicine in Neurology
  • 697 Accesses

Abstract

Mild cognitive impairment (MCI) corresponds to a slight but measurable decline in cognitive abilities, including memory and thinking skills but still in absence of a noticeable impact of their activities of daily leaving.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 89.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 119.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 169.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Suggested Reading

  • Blazhenets G, Ma Y, Sörensen A, et al. Predictive value of 18FFlorbetapir and 18FFDG PET for conversion from mild cognitive impairment to Alzheimer dementia. J Nucl Med. 2020;61:597–603.

    Article  CAS  Google Scholar 

  • Burnham SC, Bourgeat P, Doré V, Savage G, Brown B, Laws S, et al. Clinical and cognitive trajectories in cognitively healthy elderly individuals with suspected non-Alzheimer’s disease pathophysiology (SNAP) or Alzheimer’s disease pathology: a longitudinal study. Lancet Neurol. 2016;15:1044–53.

    Article  Google Scholar 

  • Dani M, Brooks DJ, Edison P. Suspected non-Alzheimer’s pathology - is it non-Alzheimer’s or non-amyloid? Ageing Res Rev. 2017;36:20–31.

    Article  CAS  Google Scholar 

  • Herholz K, Salmon E, Perani D, Baron JC, Holthoff V, Frölich L, et al. Discrimination between Alzheimer dementia and controls by automated analysis of multicenter FDG PET. Neuroimage. 2002;17:302–16.

    Article  CAS  Google Scholar 

  • Jack CR Jr, Bennett DA, Blennow K, Carrillo MC, Dunn B, Elliott C, et al. NIA-AA research framework: towards a biological definition of Alzheimer’s disease. Alzheimers Dement. 2018;14:535–62.

    Article  Google Scholar 

  • Magistretti PJ, Pellerin L. Astrocytes couple synaptic activity to glucose utilization in the brain. News Physiol Sci. 1999;14:177–82.

    CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Silvia Morbelli .

Editor information

Editors and Affiliations

Rights and permissions

Reprints and permissions

Copyright information

© 2022 The Author(s), under exclusive license to Springer Nature Switzerland AG

About this chapter

Check for updates. Verify currency and authenticity via CrossMark

Cite this chapter

Morbelli, S., Miceli, A. (2022). Case 1: Mild Cognitive Impairment (MCI)—[18F]FDG and Amyloid PET. In: Varrone, A., Morbelli, S., Garibotto, V. (eds) Clinical Nuclear Medicine in Neurology. Springer, Cham. https://doi.org/10.1007/978-3-030-83598-9_1

Download citation

  • DOI: https://doi.org/10.1007/978-3-030-83598-9_1

  • Published:

  • Publisher Name: Springer, Cham

  • Print ISBN: 978-3-030-83597-2

  • Online ISBN: 978-3-030-83598-9

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics